Limosilactobacillus reuteri NCIMB 701359
Limosilactobacillus reuteri NCIMB 701359 (formerly Lactobacillus reuteri NCIMB 701359) has been studied primarily through in vitro laboratory models. Research has examined anti-adhesion activity against oral pathogens such as Streptococcus mutans and Candida albicans, anti-proliferative activity against colorectal cancer cell lines, and cholesterol assimilation, all in laboratory settings. All available evidence for this specific strain is preclinical; no human clinical trials have been identified. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 6 body-system-tagged papers that concern each system. Research coverage, not measured effect.
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 4 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
6 papers reference this strain in the probiotic database.
Discussion
Be the first to comment.
Sign in to join the discussion.